| Authors: |
Hage C; Karolinska Institutet, Department of Medicine, Cardiology unit, Stockholm, Sweden. Electronic address: camilla.hage@sll.se., Löfgren L; Translational Science and Experimental Medicine; Research and early Development, Cardiovascular, Renal and Metabolism, Biopharmaceutical R&D, AstraZeneca, Gothenburg, Sweden., Michopoulos F; Bioscience, Early Oncology R&D, AstraZenenca, Cambridge, UK., Nilsson R; Translational Science and Experimental Medicine; Research and early Development, Cardiovascular, Renal and Metabolism, Biopharmaceutical R&D, AstraZeneca, Gothenburg, Sweden., Davidsson P; Translational Science and Experimental Medicine; Research and early Development, Cardiovascular, Renal and Metabolism, Biopharmaceutical R&D, AstraZeneca, Gothenburg, Sweden., Kumar C; Translational Science and Experimental Medicine; Research and early Development, Cardiovascular, Renal and Metabolism, Biopharmaceutical R&D, AstraZeneca, Gothenburg, Sweden., Ekström M; Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Division of Cardiovascular Medicine Stockholm, Sweden., Eriksson MJ; Karolinska Institutet, Department of Molecular Medicine and Surgery, Stockholm, Sweden., Lyngå P; Karolinska Institutet, Department of Clinical Science and Education, Sodersjukhuset, Stockholm, Sweden., Persson B; Uppsala University, Department of Cell and Molecular Biology, Science for Life Laboratory, Uppsala, Sweden., Wallén H; Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Division of Cardiovascular Medicine Stockholm, Sweden., Gan LM; Early Clinical Development, Research and early Development, Cardiovascular, Renal and Metabolism, Biopharmaceutical R&D, AstraZeneca, Gothenburg, Sweden., Persson H; Karolinska Institutet, Department of Clinical Sciences, Danderyd Hospital, Division of Cardiovascular Medicine Stockholm, Sweden., Linde C; Karolinska Institutet, Department of Medicine, Cardiology unit, Stockholm, Sweden. |
